Obesity Management

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.

Recent research data assessed the potential use of GLP-1s for reducing the progression of total knee arthroplasty.

Late-phase trials show switching to daily oral orforglipron or lower-dose tirzepatide helps maintain weight loss, easing regain and boosting adherence.

Results of Eli Lilly’s investigational triple agonist were reported in the TRIUMPH-1 Phase 3 clinical trial.

New OASIS 4 data show early oral semaglutide responders hit 21.6% weight loss and improve mobility.

The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.

Following an FDA announcement on its deeper look into peptide restrictions, Christopher Shade, PhD, joined to provide insights on their functions for metabolic health and more.

Researchers find Reddit posts provides a look at the real-world adverse effects of glucagon-like peptide-1 receptor agonists.

The FDA’s Pharmacy Compounding Advisory Committee will meet in late July of 2026 to convene on peptides and their inclusion on the 503A Bulk Drug Substances List.

Cloned pharmacy sites and fake GLP-1 weight-loss pens surge online, prompting federal crackdowns and urgent safety warnings for patients.

New 2026 guidance backs long-term obesity drugs, spotlighting GLP-1 benefits, side effects, and off-label risks pharmacists must navigate.

Tentative FDA nod for generic semaglutide signals more glucagon-like peptide-1 access, easing pharmacy hurdles and curbing risky compounded alternatives.

Episode 9 dives into the landscape of obesity pharmacotherapy, detailing current therapies, clinical updates, future pipelines, and more.

Community pharmacists weave brief lifestyle coaching and point-of-care testing into medication management, improving diabetes and hypertension outcomes.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

With a slew of new GLP-1 indications approved in recent history, researchers and experts are now diving into their use in treating substance use disorders.

Pharmacists boost chronic disease outcomes by adding quick nutrition screening, counseling, and drug-nutrient checks to everyday visits.

Orforglipron is the first new molecular entity to be cleared under the FDA Commissioner's National Priority Voucher pilot program.

The FDA clears the highest-dose weekly semaglutide for obesity, showing 20.7% mean weight loss with the same blood sugar-lowering effects.

With ongoing concerns about the safety and formulation of compounded GLP-1s, Annie Lambert, PharmD, BCSCP, added her expert insights into the recent crackdown of these products.

Annie Lambert, PharmD, BCSCP, discusses pharmacies’ regulation and compliance needs when it comes to dispensing compounded GLP-1s.

The health care landscape for metabolic liver disease is undergoing a shift, and pharmacists are being positioned at the forefront of this therapeutic revolution.

Eli Lilly flags unknown impurities in compounded tirzepatide with B12 as FDA targets misleading GLP-1 marketing.